Cat No. 28-R52

INCB-018424


#### 5mg



# For research purposes only

INCB-018424, also known as Ruxolitinib, is a potent and selective inhibitor of Janus -associated kinase 1 and 2 (JAK1,2). It acts by blocking the JAK/STAT pathway. It is also shown to selectively inhibit a wide range of other kinases including JAK3.

## **TECHNICAL INFORMATION**



# STORAGE AND HANDLING

**Storage:** Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

**Stability:** Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

#### PRODUCT USE

Soluble in DMSO. Soluble at 20mg/ml.

**Other Names:** β-Cyclopentyl-4-(7H-pyrrolo[2, 3-d] pyrimidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile

**Chemical Formula:** C<sub>17</sub>H<sub>18</sub>N<sub>6</sub>

CAS Number: 941678-49-5

Molecular Weight: 306.37

**Purity: >99%** 

Appearance: Pale Yellow Crystalline Solid

Solubility: DMSO

IC50: JAK1 3nM, JAK2 5nM, JAK3 332nM

### REFERENCES

- Mesa, R.A, et al. (2010). Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 13:394-403.
- Nagvi, K., et al. (2011). A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 20:1159-66.

